NATURAL HOLISTIC MEDICINE BLOG - Judicial police in Guinea-Bissau have conducted a raid on the offices of researchers involved in a controversial study on African newborns, seizing doses of hepatitis B vaccines. The operation, which took place on Monday, was described by officials as "investigative procedures aimed at clarifying the circumstances related to the said batch of vaccines." While the announcement, translated from Portuguese, stated that the seizure did not indicate "irregularities in the quality, safety, or effectiveness of the vaccines," the event has intensified scrutiny on the research project and its funding.
Funding and Ethical Concerns Surround Newborn Hepatitis B Study
The research at the heart of this dispute is supported by significant funding, totaling $3.2 million.
This includes $1.6 million from the U.S.
Centers for Disease Control and Prevention (CDC), with matching contributions from the Pershing Square Foundation and the Bluebell Foundation.
The study, primarily focused on African newborns, has drawn sharp criticism from global health organizations and officials over its ethical implications.
Specifically, concerns have been raised about the study's design, which, despite a redesign over the summer, would reportedly deny hepatitis B vaccines to approximately 7,000 newborns in the first six weeks of life.
This is particularly alarming in Guinea-Bissau, where an estimated one in five adults are living with the hepatitis B virus.
Hepatitis B is a serious illness that can lead to cancer and liver failure, with newborns being especially vulnerable.
Official Statements Highlight Disagreement and Health Risks
The health minister of Guinea-Bissau’s transitional government, Quinhin Nantote, has publicly disputed reports that the trial would proceed as planned.
In an interview with The Guardian on Thursday, Nantote stated unequivocally, “This is not even remotely true.” The World Health Organization (WHO) has also voiced strong opposition to any study that would withhold this vital vaccine.
Tarik Jašarević, a WHO spokesperson, emphasized that hepatitis B vaccination at birth is an "essential public health intervention" and that denying it to participants would be "unethical and exposes newborns to serious and potentially irreversible harm." The WHO, through its country office, has been actively advising the Ministry of Health in Guinea-Bissau regarding the introduction of the hepatitis B vaccine and the potential ramifications of this particular study.
Researchers' Background and Controversial Praise
The research in question is conducted by the Bandim Health Project, founded in 1978 by anthropologist Peter Aaby and now co-led by his wife, epidemiologist Christine Stabell Benn.
This project has gained a notable, albeit controversial, public profile, particularly through its association with Robert F.
Kennedy Jr.
Kennedy, who has been a vocal critic of vaccine mandates and policies, has publicly lauded the work of Aaby and Stabell Benn, referring to them as "the deities of vaccine research" at an anti-vaccine conference.
He has also cited their research on other vaccines, such as diphtheria-tetanus-pertussis (DTP), in various public forums, including a 2023 appearance on Joe Rogan's podcast, where he called Aaby "very famous" and referenced his work when advocating for the cessation of U.S. funding to Gavi, the Vaccine Alliance.
Stabell Benn's involvement extends to a role within the Advisory Committee on Immunization Practices (ACIP) hepatitis B working group, where she presented evidence that influenced discussions on vaccine recommendations in the United States.
Ethical Approvals and International Scrutiny
Despite the ongoing dispute and international concern, the Bandim Health Project recently shared evidence of ethical approval for the trial.
This included a letter of approval from Guinea-Bissau’s national ethics committee at the Ministry of Public Health, dated July 14, and signed by committee president Mouhammed Djicó Ould Ahmed.
Additionally, a Danish research ethics committee, which reportedly altered its rules to accommodate the clinical trial, also gave its approval earlier this month.
These approvals, however, have not quelled the broader ethical debates surrounding the study's design and its potential impact on vulnerable infants.
Broader Context: Fragility and Local Distrust
The situation in Guinea-Bissau, a nation that experienced a military coup less than a year prior to these events, underscores the complexities of conducting research in politically unstable environments.
Colette Delawalla, an American health researcher and founder of the non-profit Stand Up for Science (SUFS), highlighted that Guinea-Bissau is a "fragile" nation lacking the stability necessary for robust clinical trials.
SUFS's reports suggest that despite decades of operation, the Bandim organization has done little to enhance Guinea-Bissau's health and research infrastructure.
Delawalla also noted significant public distrust towards Bandim among the local population, although she acknowledged that due to the country's limited public health infrastructure, Bandim often serves as a critical, sometimes the only, avenue for medical care for desperate citizens.
She posited that Guinea-Bissau is attempting to protect its future generation from potential exploitation by powerful Western entities, utilizing its limited leverage in this situation.
Unanswered Questions and Future Implications
As of the latest reports, Peter Aaby, Christine Stabell Benn, and Frederik Schaltz-Buchholzer, the lead researcher for the project, have not responded to inquiries from The Guardian regarding the trial and the recent police search.
The seizure of vaccines and the ongoing controversy raise critical questions about research oversight, ethical conduct in global health initiatives, and the protection of vulnerable populations.
The Bandim Health Project is reportedly currently fundraising to support the rollout of vaccines at birth for all newborns in the country, a stark contrast to the disputed trial's methodology.
The international community and public health bodies will likely continue to monitor developments closely, seeking clarity on the ethical frameworks guiding such research and ensuring the well-being of infants in Guinea-Bissau.
Comments